Carbogen Amcis Overview
- Year Founded
-
2000

- Status
-
Acquired/Merged
- Employees
-
590

- Latest Deal Type
-
Corporate
- Financing Rounds
-
4
- Investments
-
1
Carbogen Amcis General Information
Description
Provider of drug development and commercialization services catering to the pharmaceutical and biopharmaceutical industries. The company offers active pharmaceutical ingredients and vitamin D analogs, cholesterol and lanolin derivatives products for preclinical studies, clinical trials and commercial use.
Contact Information
Website
www.carbogen-amcis.com(Operating Subsidiary)
Corporate Office
- Hauptstrasse 171
- 4416 Bubendorf
- Switzerland
Corporate Office
- Hauptstrasse 171
- 4416 Bubendorf
- Switzerland
Carbogen Amcis Valuation & Funding
Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
---|
Carbogen Amcis Comparisons
Industry
Financing
Details
Carbogen Amcis Competitors (13)
One of Carbogen Amcis’s 13 competitors is ANI Pharmaceuticals, a Corporation company based in Baudette, MN.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
ANI Pharmaceuticals | Corporation | Baudette, MN | ||||
Lonza Group | Corporation | Basel, Switzerland | ||||
Parexel International | Private Equity-Backed | Durham, NC | ||||
Patheon | Formerly PE-Backed | Waltham, MA | ||||
Cobra Bio-Manufacturing | Corporation | Keele, United Kingdom |
Carbogen Amcis Patents
Carbogen Amcis Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20220064125-A1 | Novel processes | Active | 19-Oct-2018 | ||
US-11724988-B2 | Processes | Active | 19-Oct-2018 | ||
GB-201304323-D0 | Bortezomib | Inactive | 11-Mar-2013 | ||
US-9695185-B2 | Synthetic methods for spiro-oxindole compounds | Inactive | 14-Oct-2009 | ||
US-20160326184-A1 | Synthetic methods for spiro-oxindole compounds | Active | 14-Oct-2009 | C07D491/20 |
Carbogen Amcis Signals
Carbogen Amcis Former Investors
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
---|
Carbogen Amcis Acquisitions (1)
Carbogen Amcis’s most recent deal was a Merger/Acquisition with Creapharm Parenterals. The deal was made on 16-Jan-2012.
Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
---|---|---|---|---|---|
Creapharm Parenterals | 16-Jan-2012 | Merger/Acquisition | Biotechnology |
Carbogen Amcis FAQs
-
When was Carbogen Amcis founded?
Carbogen Amcis was founded in 2000.
-
Where is Carbogen Amcis headquartered?
Carbogen Amcis is headquartered in Bubendorf, Switzerland.
-
What is the size of Carbogen Amcis?
Carbogen Amcis has 590 total employees.
-
What industry is Carbogen Amcis in?
Carbogen Amcis’s primary industry is Other Healthcare Services.
-
Is Carbogen Amcis a private or public company?
Carbogen Amcis is a Private company.
-
What is Carbogen Amcis’s current revenue?
The current revenue for Carbogen Amcis is
. -
Who are Carbogen Amcis’s investors?
Solutia has invested in Carbogen Amcis.
-
Who are Carbogen Amcis’s competitors?
ANI Pharmaceuticals, Lonza Group, Parexel International, Patheon, and Cobra Bio-Manufacturing are some of the 13 competitors of Carbogen Amcis.
-
When was Carbogen Amcis acquired?
Carbogen Amcis was acquired on 15-Aug-2021.
-
Who acquired Carbogen Amcis?
Carbogen Amcis was acquired by Dishman Carbogen Amics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »